ClinicalTrials.gg

Rhinitis, Allergic, Perennial clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 178 studies for Rhinitis, Allergic, Perennial across more than 10 countries. 9 are recruiting or about to start. 143 of them are mainly about Rhinitis, Allergic, Perennial (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27. Counting its narrower condition Dust Mite Allergy too: 219 studies, 14 open.

Status

Completed
155
Status unknown
8
Not yet recruiting
6
Terminated
3
Recruiting
3
Withdrawn
2

Phase

Phase 3
82
Phase 4
34
Phase 2
19
Phase 1
15

Where

United States
60
Korea, Republic of
16
Canada
9
China
8
Japan
7
Germany
6

Who develops what

Add Rhinitis, Allergic, Perennial to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months. Compare AJU Pharm, HALEON and Jemincare here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Mometasone FuroateEarlier only
Evidence
  • NCT02498509 · Chong Kun Dang Pharmaceutical · Phase 3 · comparator · “Mometasone furoate” · registered Jul 2015
  • NCT01470053 · hanlim pharm · Phase 3 · comparator · “mometasone furoate” · registered Nov 2011
  • NCT01401465 · Sumitomo Pharma Co., Ltd. · Phase 3 · comparator · “mometasone” · registered Jul 2011
  • NCT01287364 · Sumitomo Pharma Co., Ltd. · Phase 3 · background · “mometasone nasal inhalation” · registered Jan 2011
  • NCT00224523 · GlaxoSmithKline · Phase 3 · background · “mometasone furoate” · registered Aug 2005
Organon & Co.62% of its industry studiesUS: off-patent, 12 generics marketed00 studies
FluticasoneEarlier only
Evidence
  • NCT03317015 · Sanofi · Phase 3 · comparator · “fluticasone” · registered Oct 2017
  • NCT00783224 · Organon & Co. · Phase 3 · comparator · “Fluticasone” · registered Oct 2008
GlaxoSmithKline35% of its industry studiesUS: off-patent, 25 generics marketed00 studies
CetirizineEarlier only
Evidence
  • NCT01127620 · Faes Farma, S.A. · Phase 3 · comparator · “Cetirizine” · registered May 2010
  • NCT00974571 · Organon & Co. · Phase 3 · comparator · “Comparator: cetirizine” · registered Sep 2009
Organon & Co.18% of its industry studiesUS: off-patent, 40 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Fluticasone · haleon · Phase 4 main aimNCT07817134 A Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis — primary endpoint: Visualization of Facial Allergy Symptoms · 16 enrolled
  • Oct 2027 est.ozureprubart · Jemincare · Phase 2 main aimNCT07459452 Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis — primary endpoint: Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo) · 135 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Rhinitis, Allergic, Perennial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 1 open · Antihistamines 32

Coming up

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, 0 (0%) set no upper age limit and 3 (100%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 3
AgeWomenMen
100 (0%)0 (0%)
182 (67%)2 (67%)
303 (100%)3 (100%)
403 (100%)3 (100%)
503 (100%)3 (100%)
651 (33%)1 (33%)
750 (0%)0 (0%)
850 (0%)0 (0%)

Across all 178 studies, recruiting or not: 56% stop at 75 or younger and 52% at 65; 62% take children; 0% are for women only and 2% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rhinitis, Allergic, Perennial studies take

Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 38 mo2–15 · 17 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 178. Browse all 178 → or search them.